French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that it has entered into a strategic partnership with Orano Med, a developer of targeted alphatherapies in oncology and a subsidiary of the Orano Group, to develop innovative radioligand therapies for rare cancers.
This collaboration leverages Orano Med's expertise and radioligand pipeline and Sanofi's capabilities in drug discovery and development.
The partnership will focus on the discovery, design and clinical development of next-generation radioligand therapies based on lead-212 alpha-emitting isotopes. Sanofi's investment of EUR300m will further strengthen Orano Med and accelerate the development of its pipeline.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient